Start the conversation
That's because British medical technology company Smith & Nephew PLC will buy ArthroCare in a $1.7 billion all-cash deal, a move aimed at tackling the growing sports medicine industry.
Smith & Nephew announced Monday it will pay $48.25 for each share of Austin, Texas-based ArthroCare, a roughly 6% premium to its closing price of $45.38 on Friday.
The British company believes ArthroCare's shoulder joint repair expertise will nicely complement its knee and hip repair segment and generate "significant additional revenue."
"We wanted to acquire in high-growth businesses and sports medicine is definitely one of them," Smith & Nephew Chief Executive Officer Olivier Bohuon said in a statement.
Indeed, the lucrative sports medicine device market is expected to reach $5.7 billion by 2017, a 9.3% increase from 2011, according to MarketsandMarkets, a Texas-based global reach and consulting company. Reasons cited include an increase in the number of professional and nonprofessional players and the growing popularity of team and individual sports.
Revenue at the British firm's sports medicine business has been growing at 7%, while its hip and knee replacement segment is growing by 5%. Smith & Nephew expects the deal will add approximately $85 million to annual trading profit in the third full year as a combined entity.
ArthroCare, which makes surgical devices, instruments, and implants, also sports an ENT (ear, nose, and throat) franchise that can be developed outside the United States, Bohuon added.
Some 68% of ArthroCare sales come from America, while Smith & Nephew generates most of its revenue in Europe and emerging markets. Selling products to a more global market should be "a relatively straightforward exercise," Jones added.
"The acquisition of ArthoCare makes clear strategic sense; it makes the company a leader in sports medicine and expands its reach into the ENT market, thereby improving its long-term growth prospects," Mike Cooper, an analyst at Edison Investment Research, told Reuters.
And the gains could keep going for ARTC investors...